| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ff40e5f9fe4a871b3c1ef0cdccfa05a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2017-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a99ae4803b9736c704b09f4c173a4379
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07bde6bdef933a87a3cb10b025f29924
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_347c4bae87f4ebfb8be0b0dce1d9662d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b18a5a012b800a1df33284777fca5d1 |
| publicationDate |
2019-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109153720-A |
| titleOfInvention |
Diagnosis of immune activation using CLEVER-1, TNF-α and HLA-DR binders |
| abstract |
An agent capable of binding CLEVER-1 in an individual can be used to activate macrophages to switch their phenotype from M2 macrophages to M1 macrophages. The present invention relates to methods for exploiting the ability of macrophages to switch their phenotype. In one aspect, the invention relates to a method for assessing the efficacy of anti-CLEVER-1 therapy by monitoring the modulation of M2 macrophages to M1 macrophages when an agent capable of binding CLEVER-1 is administered in a patient, wherein TNF-alpha is secreted Or increased HLA-DR expression indicates regulation of M2 macrophages to M1 macrophages. |
| priorityDate |
2016-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |